NCI and Thermo Fisher Launch Phase 2 Screening for 'Venetoclax' and Other Targeted Therapies for AML and MDS
1. Implementation of a Next-Generation Companion Diagnostic Platform Based on Precision Medicine
The 'MyeloMATCH' (NCT05564390) study, led by the National Cancer Institute (NCI) and in collaboration with Thermo Fisher Scientific (NYSE: TMO), is an innovative Phase 2 clinical trial screening study for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It aims to move beyond conventional, uniform chemotherapy by rapidly analyzing the individual genetic information of patients and matching them with the most appropriate targeted therapies. In particular, the introduction of Thermo Fisher's automated NGS analysis equipment, the Ion Torrent Genexus system, enables the provision of NGS analysis results within just 72 hours, securing the critical treatment window. This is considered a significant advancement, especially in the field of acute blood cancers where rapid treatment decisions are directly linked to survival rates.
2. Building a Comprehensive Clinical Portfolio and Personalized Treatment Pathways
This study goes beyond a simple one-time diagnosis and implements a tiered advancement pathway (TAP) that allows patients to continuously transition to appropriate clinical trials based on the stage of their disease. The matching list includes representative targeted and demethylating agents such as venetoclax (Venetoclax) from AbbVie (ABBV), azacitidine (Azacitidine), and decitabine (Decitabine) from Bristol Myers Squibb (BMS, BMY). By organically combining companion diagnostics with multiple targeted anticancer drug clinical trials, patients can continuously receive the optimal drug based on treatment response and changes in genetic mutations. Researchers expect that this multi-target clinical matching architecture will become the standard for master protocols that will change the treatment paradigm for patients with refractory cancers in the future.
3. Transforming the Blood Cancer Market and Maximizing Pharmaceutical R&D Efficiency
The global AML therapeutics market is currently estimated at $3.1 billion to $4.3 billion, and the MDS therapeutics market is also around $2.4 billion to $5.3 billion. Both diseases are expected to grow into large markets of around $10 billion each by the mid-2030s, driven by the aging population and the development of precision diagnostic technologies. From a pharmaceutical company's perspective, participating in the MyeloMATCH platform is a strategic opportunity to dramatically shorten the target patient recruitment period and significantly increase the success rate of clinical trials. Ultimately, it will undoubtedly serve as a catalyst for maximizing the pipeline value of global big pharma and innovative biotech companies through the double benefits of reducing clinical costs and shortening the new drug launch period.
4. Competition for Market Leadership Against Standard Treatments and Competing Platforms
The most prominent competing model for MyeloMATCH is the 'Beat AML' master clinical trial led by the Leukemia & Lymphoma Society (LLS). In a situation where Beat AML has taken the lead in the market by utilizing NGS technology from Foundation Medicine, a subsidiary of Roche, the NCI-led national project, MyeloMATCH, is aggressively pursuing it with the backing of the National Clinical Trial Network (NCTN) across North America. The industry believes that this competition between precision medicine platforms will promote technological innovation in the overall diagnostic device and targeted anticancer drug markets. Ultimately, it is a business momentum that will have a significant impact on the expansion of market share in the companion diagnostic NGS device market and on exclusive licensing agreements for targeted therapies by pharmaceutical companies.
The NCI-led MyeloMATCH Phase 2 screening platform has a short-term impact by shortening the genetic analysis period for clinical trial participants to within 72 hours, solving the patient recruitment bottleneck, and drastically reducing the new drug development period. In the medium to long term, it will establish itself as a strong alternative to existing competing diagnostic platforms such as LLS's 'Beat AML' in the global AML ($3.1 billion to $4.3 billion) and MDS ($2.4 billion to $5.3 billion) markets, and redefine the standards for precision medicine clinical trials. The adoption of Thermo Fisher Scientific's (TMO) NGS system is a compelling growth driver for investors as it will lead to increased sales of the company's diagnostic devices. For researchers and clinical coordinators, it provides an opportunity to accumulate know-how in multi-target matching based on molecular biological biomarkers, and is expected to serve as a catalyst for activating the precision cancer research ecosystem.
Source: ClinicalTrials.gov (api_ct)